Skip to main content

Raxibacumab FDA Approval History

FDA Approved: Yes (First approved December 14, 2012)
Generic name: raxibacumab
Company: Emergent BioSolutions Inc.
Treatment for: Anthrax

Raxibacumab is a human monoclonal antibody drug for the treatment of inhalational anthrax.

Development timeline for raxibacumab

DateArticle
Dec 14, 2012Approval FDA Approves Raxibacumab to Treat Inhalational Anthrax
Jul 10, 2012Human Genome Sciences Announces Resubmission of Raxibacumab BLA to FDA
Nov 16, 2009Human Genome Sciences Receives Complete Response Letter from FDA for Raxibacumab Biologics License Application
May 21, 2009Human Genome Sciences Submits Biologics License Application to FDA for ABthrax

See also

raxibacumab Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer